Evidence map›Paper›PMID 37382253›Full record

Trial reportImmunity, inflammation and disease2023

The effect of oral probiotics on CD4 count in patients with HIV infection undergoing treatment with ART who have had an immunological failure.

Masoud Mortezazadeh, Saeed Kalantari, Nooshin Abolghasemi, Mitra Ranjbar, Saeedeh Ebrahimi, Abbas Mofidi, Babak Pezeshkpour, Ensieh Sadat Mansouri, Seyed Zia Tabatabaei, Mehdi Kashani

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Masoud MortezazadehInternal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-3585-9379
Saeed KalantariDepartment of Infectious Disease, Antimicrobial Resistance Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Nooshin AbolghasemiDepartment of Pharmacology, Islamic Azad University Pharmaceutical Sciences Branch -Pharmacy School, Tehran, Iran.
Mitra RanjbarDepartment of Infectious Disease, Firoozgar General Hospital, Iran University of Medical Sciences, Tehran, Iran.
Saeedeh EbrahimiDepartment of Infectious Disease, Alborz University of Medical Sciences, Karaj, Iran.
Abbas MofidiDepartment of Infectious Disease, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Babak PezeshkpourDepartment of Infectious Disease, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Ensieh Sadat MansouriInternal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Zia TabatabaeiInternal Medicine Department, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-9534-4898
Mehdi KashaniDepartment of Infectious Disease, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-6868-6481
Iran University of Medical Sciences · IRSina Hospital · IRIslamic Azad University Pharmaceutical Sciences Branch · IRJahrom University of Medical Sciences · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProbiotics are live microorganisms that, when administered in appropriate colonies, can delay the destruction of the immune system and contribute to the maintenance of immunity in HIV patients. Probiotics play an important role in stimulating natural killer T cells, strengthening the functional gut barrier, and reducing systemic inflammation.

methodsThis study was a randomized double-blind clinical trial involving 30 patients treated with antiretroviral therapy who had experienced immunological failure despite HIV viral suppression. Patients were divided into two equal groups of 15, group (B) received two probiotic capsules daily with a colony count of 10⁹ CFU per capsule containing seven strains, after 3 months they were examined for CD4

resultsIn the first group (A), administration of the placebo resulted in a decrease in CD4 count in the first 3 months (from 202.21 to 181.79, p value < .001), which may be due to the natural history of the disease. After probiotics administration, CD4 count increased significantly (from 181.79 to 243.86, p value < .001). Overall, after 7 months of study, there was a significant increase in the mean CD count from 202.21 to 243.86 (p value < .001). In the second group (B), the administration of probiotics in the first 3 months of the study resulted in a significant increase in the mean CD4 count (from 126.45 to 175.73, p value < .001). Termination of treatment with probiotics resulted in a significant decrease (from 175.73 to 138.9, p value < .001) but overall the CD4 count at the end of the study was significantly higher than at baseline (p value < .001).

Indexed as

HIV InfectionsProbioticsCD4 Lymphocyte CountFlow CytometryHumansInflammationCD4HIVimmunologic failureprobioticvirologic response

Identifiers

PMID37382253
PMCPMC10266137
OpenAlexW4380681928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.